Akanksha Sharma, M.D.
Investigator
Dr. Akanksha Sharma is a neuro-oncologist and physician leader specializing in the care of patients with primary and metastatic brain tumors. She currently serves as Medical and Research Director of Neuro-Oncology at Sutter Health/California Pacific Medical Center in San Francisco.
Dr. Sharma completed her neurology residency at the University of Washington, where she served as Chief Resident, followed by fellowships in Neuro-Oncology at Mayo Clinic Arizona and Hospice and Palliative Medicine at the University of Washington.
Her clinical and research work focuses on improving quality of life and integrating palliative care into neuro-oncology. She has led and contributed to numerous clinical studies, including investigator-initiated research on brain tumors, caregiving burden, and innovative therapeutic approaches.
An active leader in the field, Dr. Sharma is involved with national and international organizations including the American Academy of Neurology, Society of Neuro-Oncology, and American Society of Clinical Oncology, and serves in multiple advisory and leadership roles.
She is widely published in peer-reviewed journals and recognized for her contributions to neuro-oncology research, education, and patient-centered care.
Clinical trials
- Clinical trial
Adjuvant Grade II or III Meningioma JZP3507-202
A Phase 2 Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP3507 (ONC206) in Adults With Recurrent Grade 2 or 3 Meningioma
Status: Open to Enrollment
- Clinical trial
Metastasis Brain NEO212-01
An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients With Select Solid Tumors
Status: Open to Enrollment
- Clinical trial
Neoadjuvant Glioblastoma GTM-105
Randomized Study of Resection and GammaTile® Followed by Concurrent External Beam Radiation Therapy (EBRT) and Temozolomide (TMZ) and Adjuvant TMZ Versus Standard of Care in Newly Diagnosed Glioblastoma (GBM)
Status: Open to Enrollment
- Clinical trial
Recurrent Glioblastoma SC9-GBM-03
A Randomized, Open-label, Multicentric, Two-arm Pivotal Trial of SonoCloud-9 Combined With Carboplatin (CBDCA) vs Standard of Care Lomustine (CCNU) or Temozolomide (TMZ) in Patients Undergoing Planned Resection for First Recurrence Glioblastoma.
Status: Open to Enrollment
- Clinical trial
Recurrent or Progressive IDH1 Mutated Glioma NEO100-01
An Open-Label, Phase 1/2A Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent or Progressive Grade III or Grade IV Gliomas With IDH1 Mutation
Status: Open to Enrollment